analyzeportfolio
NYSE · Financials

Dolby Laboratories, Inc. (DLB)

As-reported financials and SEC filings for Dolby Laboratories, Inc. The latest annual period is FY2025. The latest reported quarter is Q3 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Dolby Laboratories, Inc.

Dolby Laboratories, Inc. develops and licenses audio and video technologies that enhance entertainment experiences. Its main products include branded audio codecs like DD+ and Dolby AC-4, as well as Dolby Atmos and Dolby Vision technologies, which provide immersive sound and high dynamic range video. The company serves content creators, distributors, and approximately 1,000 consumer electronics manufacturers worldwide by licensing its technology for use in devices such as home theaters, smartphones, and TVs.

Snapshot

Revenue
$1.35B
Revenue growth (YoY)
5.9%
Net income
$255.0M
Diluted EPS
$2.62
Gross margin
88.1%
Operating margin
19.6%
Net margin
18.9%
FCF margin
32.3%
ROE
9.7%
net income / fiscal-year-end equity
P/E
24.7×
trailing when available, otherwise FY EPS
Market cap
$5.47B
Long-term debt / equity
—
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended September 26, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Dolby Laboratories

  • Revenue grew 5.9% to $1.3B in FY2025, after a 2.0% decline the year before.
  • Operating margin is 19.6% in FY2025, -7.2 pp against 26.9% in FY2021.
  • Most recent quarter Q3 FY2026: revenue $305M, down 3.3% from Q3 FY2025.
  • Free cash flow was $436M in FY2025, 32.3% of revenue.
  • Net income fell 2.6% to $255M in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Dolby Laboratories’s fundamentals sit among the 424 Financials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Gross margin88.1%
96th percentile of 48
Operating margin19.6%
57th percentile of 141
Net margin18.9%
57th percentile of 372
FCF margin32.3%
74th percentile of 266
Revenue growth (YoY)+5.9%
34th percentile of 418
ROE9.7%
51st percentile of 373
P/E24.7×
83rd percentile of 307
Short interest5.86d
79th percentile of 419

Dolby Laboratories’s gross margin of 88.1% ranks in the 96th percentile of the 48 Financials companies reporting it.

No reported insider purchases (code P) in the last 90 days; 9 insider sales totaling $1.7M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 2 of the superinvestors we track (plus 5 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
2
+5 quant / multi-strat
Initiated / added
5
2 new, 3 added
Reduced / exited
2
2 trimmed, 0 exited
Combined position
$114.0M
reported long value
InvestorAs ofPosition valueSharesChange
Citadel AdvisorsquantQ2 2026$30.6M582.0KAdded
Millennium ManagementquantQ2 2026$22.1M420.1KReduced
D. E. ShawquantQ2 2026$21.8M415.0KAdded
Gotham Asset ManagementQ2 2026$17.7M336.0KAdded
AQR Capital ManagementquantQ2 2026$16.9M322.7KReduced
Bridgewater AssociatesQ2 2026$3.2M60.3KNew
Two Sigma InvestmentsquantQ2 2026$1.7M33.0KNew

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
—
code P value
Sells (90d)
9
$1.7M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-10-01
filed 2026-10-05
John D. CoulingSVP, EntertainmentSell6.8K$58.72$401K
2026-10-01
filed 2026-10-05
John D. CoulingSVP, EntertainmentSell836$59.33$50K
2026-09-01
filed 2026-09-03
John D. CoulingSVP, EntertainmentSell7.7K$61.05$468K
2026-08-25
filed 2026-08-27
Ryan NicholsonVP, CAO and Corp. ControllerSell1.2K$65.28$77K
2026-08-14
filed 2026-08-18
Shriram RevankarSVP, Advanced Technology GroupSell3.0K$62.71$188K
2026-08-10
filed 2026-08-12
Ryan NicholsonVP, CAO and Corp. ControllerSell1.3K$62.04$84K
2026-08-04
filed 2026-08-06
Ryan NicholsonVP, CAO and Corp. ControllerSell357$60.63$22K
2026-08-03
filed 2026-08-05
John D. CoulingSVP, EntertainmentSell6.9K$60.11$414K
2026-08-03
filed 2026-08-05
John D. CoulingSVP, EntertainmentSell783$59.03$46K
2026-07-01
filed 2026-07-06
John D. CoulingSVP, EntertainmentSell7.7K$53.20$408K
2026-06-01
filed 2026-06-03
John D. CoulingSVP, EntertainmentSell7.2K$55.59$398K
2026-06-01
filed 2026-06-03
John D. CoulingSVP, EntertainmentSell508$56.16$29K

Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
5.9M
settled 2026-09-30
Change vs prior
+7.4%
vs previous settlement
Days to cover
5.86
at avg daily volume
Avg daily volume
1.0M
FINRA reported
SettlementShares shortChangeDays to cover
2026-09-305.9M+7.4%5.86
2026-09-155.5M-0.0%6.01
2026-08-315.5M-6.1%5.53
2026-08-145.9M-6.6%6.52
2026-07-316.3M-6.7%6.47
2026-07-156.8M+3.5%6.95
2026-06-306.5M+12.8%6.05
2026-06-155.8M+15.7%7.95

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$1.35B$1.27B$1.30B$1.25B$1.28B
Gross profit
Operating income$265.0M$258.3M$215.8M$206.6M$344.4M
Net income$255.0M$261.8M$200.7M$184.1M$310.2M
Diluted EPS$2.62$2.69$2.05$1.81$2.97

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$701.9M$482.0M$745.4M$620.1M$1.23B
Current assets$1.39B$1.19B$1.49B$1.31B$1.76B
Total assets$3.23B$3.11B$2.98B$2.69B$3.11B
Current liabilities$437.8M$417.8M$422.2M$277.5M$315.7M
Long-term debt—————
Total liabilities$595.8M$623.0M$607.6M$438.5M$501.5M
Total equity$2.63B$2.49B$2.37B$2.25B$2.60B

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$472.2M$327.3M$367.1M$318.6M$447.8M
Capital expenditure$36.3M$30.0M$30.3M$47.9M$54.5M
Free cash flow

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.

Quarterly trend

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q3 FY2026$305.0M-3.3%$28.6M$0.30
Q2 FY2026$395.6M7.1%$94.9M$0.99
Q1 FY2026$346.7M-2.9%$53.3M$0.55
Q4 FY20250.7%
Q3 FY2025$315.5M9.3%$46.1M$0.48
Q2 FY2025$369.6M1.4%$91.8M$0.94
Q1 FY2025$357.0M13.1%$67.8M$0.70
Q4 FY20244.9%

Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.

Company facts

ExchangeNYSE
SectorFinancials
SIC industryPatent Owners & Lessors
Latest annual periodFY2025 (ended September 26, 2025)
Latest reported quarterQ3 FY2026 (ended June 26, 2026)
Oldest indexed filing2015
SEC CIK1308547

Selected SEC filings

10-Q2026-07-30
View on EDGAR →
10-Q2026-04-30
View on EDGAR →
8-K2026-08-27
View on EDGAR →
8-K2026-07-30
View on EDGAR →
8-K2026-04-30
View on EDGAR →
8-K2026-02-06
View on EDGAR →

Largest Financials peers

All Financials companies →

Monitor DLB

Get an alert when Dolby Laboratories files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor DLB free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.